Montu has become embroiled in another contentious product dispute as the company faced accusations it misled patients over the availability of Altum Group’s Kind Medical range of medicine.

Altum said it has been contacted by several “confused and distressed” patients of Montu’s Alternaleaf clinic network saying they were told Kind Medical is out of stock.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Join the Conversation

1 Comment

  1. Medicinal cannabis clinics that restrict their prescriber access to all available medicinal cannabis products are not about patient access. No medicinal cannabis supplier (nor any clinic or dispensary formulary) stocks every available strain, dosage form or product. This approach limits patient and prescriber access to the most suitable medicine for that individual patient. It is an approach which prioritises something other than patient access.
    If we are to have a healthy, ethical and prosperous industry then we need to separate the clinical and fiscal imperative. They can exist together, but the clinical needs to have priority.